IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

oplicant: Jorg J. Goronzy et al.

Art Unit : Unknown

Serial No.: 09/723,000

Examiner: Unknown

Filed

: November 27, 2000

Title

METHODS AND MATERIALS FOR EVALUATING RHEUMATOID

ARTHRITIS

BOX SEQUENCE

Commissioner for Patents Washington, D.C. 20231

TRANSMITTAL LETTER

The following documents relating to this application are enclosed.

- Response to Notice to Comply with Requirements for Patent Applications 1. Containing Nucleotide and/or Amino Acid Sequences (5 pages);
- Copy of Notice to Comply with Requirements (1 page); 2.
- Statement Under 37 CFR §§1.821(f) and (g) (1 page); 3.
- 4. Verified Statement Under 37 CFR §1.821(f);
- Paper copy of Sequence Listing (5 pages); 5.
- Computer-readable copy of Sequence Listing (1 disk); and 6.

RECEIVED

Please apply any charges or credits to Deposit Account No. 06-1050.

MAR 1 5 2004

Respectfully submitted,

TECH CENTER 1600/2900

March 22 2001

J. Patrick Finn III, Ph.D.

Reg. No. 44,109

Fish & Richardson P.C., P.A. 60 South Sixth Street **Suite 3300**

Minneapolis, MN 55402 Telephone: (612) 335-5070 Facsimile: (612) 288-9696

60036206.doc

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

March 22, 2001

Date of Deposit

Signature

Typed or Printed Name of Person Signing Certificate



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Jorg J. Goronzy et al.

Art Unit : Unknown

Serial No.: 09/723,000

Examiner: Unknown

Filed

: November 27, 2000

Title

: METHODS AND MATERIALS FOR EVALUATING RHEUMATOID

ARTHRITIS

BOX SEQUENCE

Commissioner for Patents Washington, D.C. 20231

STATEMENT UNDER 37 CFR §§1.821(f) AND (g)

I hereby state, as required by 37 C.F.R. §1.821(f), that the content of the paper and computer-readable copy of the Sequence Listing, submitted in accordance with 37 C.F.R. §§1.821(c) and (e), respectively, are the same.

I hereby state, as required by 37 C.F.R. §1.821(g), that the enclosed submission include no new matter.

Respectfully submitted,

Date: March 22,20

J. Patrick Finn III, Ph.D.

Reg. No. 44,109

Fish & Richardson P.C., P.A. 60 South Sixth Street **Suite 3300**

Minneapolis, MN 55402 Telephone: (612) 335-5070

Facsimile: (612) 288-9696

20180687.doc

RECEIVED

MAR 1 5 2004

TECH CENTER 1600/2900

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

March 22, 2001 Date of Deposit

Signature

Typed or Printed Name of Person Signing Certificate

DISK TO STIC

MAR 0 8 2004 E

DATE:



United States Patent and Trademark Office

COMMISSIONER FOR PATENTS UNITED STATES PATENT AND TRADEMARK OFFICE WASHINGTON, D.C. 20231

APPLICATION NUMBER

FILING/RECEIPT DATE

FIRST NAMED APPLICANT

ATTORNEY DOCKET NUMBER

09/723,000

11/27/2000

Jorg J. Goronzy

07039-170002

Mark S Ellinger PhD Fish & Richardson PC PA 60 South Sixth Street Suite 3300 Minneapolis, MN 55402



Date Mailed: 01/22/2001

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE **DISCLOSURES**

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):
 - This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).
 - A copy of the "Sequence Listing" in computer readable form has not been submitted as required under 37 CFR 1.821(e).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-1123
- For CRF Submission Help, call (703) 308-4212
- Patentin Software Program Support
- For Technical Assistance, call (703) 287-0200
- To Purchase Patentin Software, call (703) 306-2600

RECEIVED

MAR 1 5 2004

TECH CENTER 1600/2900

A copy of this notice MUST be returned with the reply.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE

PATENT ATTORNEY DOCKET NO.: 07039 170002
The Patent and Trademark Office date stamp sets forth the date of receipt of:
Applicant or Patentee <u>brg. Goronzy</u> and Carnelia M. Weyand No. (Application, Appeal, Interference, Patent, Reexam) (29/723, 000 Filing or Issue Date <u>November 27, 200</u> Title: Methods and Materials For Evaluating Rheumatoid Arthr. + is [Transmittal Letter (* Copies) [] With Pet. for Ext.
[] Assignment [] Status Inquiry [] Amendment/Response 5 Pages [] Declaration
[] Maintenance Fee [] Request Certificate of Correction [] Check \$
[] Prior Art References-Number of References
[] Notice of Missing Parts [] Combined Declaration and Power of Attorney
[] Small Entity Statement C1P5]
Statement under 37 CFR [182] and B; Verified Statement under 37 CFR (189) Paper (apy Sequence (50c)
Computer Disk Squerce (I DISK), Cour of Notice to Legurements
Atty/Sec. Client/ Initials XF/J9H Matter Name Mayo Date 3/22/0)

RECEIVED

APR | 0 2001

MAR 1 5 2004

TECH CENTER 1600/2900